The landscape of vaccines in Australia is marked by stringent guidelines and a competitive marketplace and above all a focus on patient outcomes.
Biointelect partnered with a pharmaceutical company, well-versed in the Australian market but new to the vaccine domain, to develop a roadmap that would not only introduce their new vaccine but also potentially secure it a coveted position on the National Immunisation Program (NIP) with premium pricing.
Introduction The European medical market is the second-largest medical device market following the US, requiring newfound innovation for pharmaceutical companies to reach success. A US Biotech firm, on the cusp of introducing a groundbreaking first-in-class vaccine, sought Biointelect’s expertise to illuminate their path in this intricate and highly saturated market. With Biointelect’s strategic guidance and […]
Antimalarial drugs have been instrumental in saving millions of lives. Yet, with the rise of resistance to existing medications, there emerges a critical need for innovative treatments and increased accessibility to newfound medications.
With this difficult mission in mind, US pharmaceutical company 60 Degree Pharmaceuticals (60P) enlisted the strategic service of Biointelect to introduce Tafenoquine (TQ) to the United States and Australian markets.
Through a virtual drug development model, Biointelect’s joint efforts with 60P spanned four years and helped to redefine antimalarial drug availability in these markets. This partnership saw first prophylactic antimalarial drug approval by the FDA and TGA in nearly two decades.